Go to the list of all blogs
AI dvisor's Avatar
published in Blogs
Nov 12, 2026
TickeronGET DAILY SIGNALS
ADARx Pharmaceuticals (ADRX): Can It Reach $34 With +155% Upside?

ADARx Pharmaceuticals (ADRX): Can It Reach $34 With +155% Upside?

Key Takeaways

  • The central $34 target is the arithmetic mean of four verified analyst price targets issued in October 2026, rounded from roughly $34.25.
  • The individual targets range from $32 to $38, with ratings of Overweight, Buy, and Outperform across the covering firms.
  • At a recent price of $13.30, reaching $34 would require a gain of about 155%, a very large move relative to current levels.
  • The strongest supporting factor is a broad, potentially multi-blockbuster siRNA pipeline spanning cardiovascular, rare-disease, and metabolic programs.
  • The biggest risk is that ADRX is a pre-revenue biotech whose valuation depends heavily on clinical data readouts and future capital needs.

What the Analysts Are Saying

Coverage of ADRX is new and concentrated: the company completed its initial public offering in 2026, and most major initiations arrived on October 20, 2026. Four firms published price targets. JPMorgan initiated with an Overweight rating and a $38 target, UBS with a Buy and $35, and both Morgan Stanley and LifeSci Capital with $32 targets (Overweight and Outperform, respectively). TD Cowen's Tyler Van Buren also reiterated a Buy rating without publishing a fresh target.

Calculating the mean of the four valid targets gives about $34.25, which rounds to the $34 central target used here. The range is relatively tight at $32 to $38, and every covering analyst is constructive, so there is no true "cautious" camp in the published data. Morgan Stanley cited a "derisked" siRNA platform and multiple blockbuster opportunities, while JPMorgan pointed to two proprietary technologies that address limitations of first-generation siRNA approaches and called current levels an attractive entry point. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

ADRX closed near $13.30 in early November 2026, well below its 52-week high of about $23.21 set in late September and not far above its 52-week low of roughly $12.50. To reach $34, the stock would need to climb roughly 155%, which is a very large move even by the standards of volatile biotech equities.

The company is pre-revenue, so traditional valuation metrics such as P/E (price-to-earnings) are not meaningful; its market capitalization is roughly $1.4 billion. The path toward the target would depend primarily on clinical catalysts, not quarterly earnings growth. Lead programs include Agazisiran, a complement factor B candidate described as a "pipeline-in-a-product"; Onvuzosiran for the prevention of hereditary angioedema (HAE) attacks; and ADX-626, a Factor XI program for secondary stroke prevention, alongside earlier-stage obesity and Alzheimer's efforts.

What Could Support a Move Toward the Target

Positive Phase 2 or Phase 3 data on Agazisiran, Onvuzosiran, or ADX-626 could materially re-rate the shares, as could a partnership or licensing deal that validates the platform and extends the cash runway. The unanimous bullish analyst posture reflects confidence in the breadth of the pipeline and the durability of siRNA-based therapies, which aim for infrequent, long-lasting dosing. A broader risk-on rotation into biotechnology could also provide a tailwind for speculative, development-stage names.

What Could Prevent the Target From Being Reached

The principal risk is clinical: disappointing efficacy or safety data in any lead program would undermine the multi-blockbuster thesis that supports the current targets. As a pre-revenue company, ADRX will likely need additional capital, and a dilutive equity raise could pressure the stock. The sharp decline from the IPO high also indicates weak post-offering investor sentiment, and biotech valuations can compress quickly when interest rates stay elevated or risk appetite fades. The tight analyst range reflects limited history, not necessarily agreement on a smooth path upward.

Technical Levels and Market Structure

Because ADRX has a short public trading history, its chart is defined by the IPO and its aftermath. The 52-week low near $12.50 is the clearest support level, while the September high near $23.21 marks the first major overhead resistance zone. Between the current price and the target, the stock would need to reclaim the roughly $14-to-$15 zone, then the IPO high near $23, before any move toward the $30s could be considered. Round-number levels such as $20 and $30 may also act as psychological barriers. From what I see, monitoring these levels with AI-driven pattern tools can add useful context.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the actual horizon varies by firm and no uniform timeline has been disclosed for these initiations. Investors should watch upcoming clinical data readouts for the lead siRNA programs, pipeline updates, any partnership or financing announcements, and the pace of cash consumption. Because there are no earnings in the conventional sense, trial milestones and regulatory feedback will matter far more than quarterly financial results. I’m watching this closely as data catalysts approach.

Final Assessment

The $34 target for ADRX represents the average of four early, uniformly bullish analyst targets ranging from $32 to $38. From a recent price near $13.30, reaching that level would require a gain of roughly 155%, a very large move that depends overwhelmingly on positive clinical outcomes and successful execution across a promising but unproven pipeline. The breadth of the siRNA portfolio and its multi-blockbuster potential are the strongest supports, while clinical failure, dilution, and weak post-IPO sentiment are the principal obstacles. Investors should monitor upcoming trial data, partnerships, and financing events rather than treating the average target as a forecast or a guarantee.

AI Daily Buy/Sell Signals

In my own analysis, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of momentum shifts. These AI-driven signals monitor thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold recommendations based on technical behavior and market conditions. For a catalyst-driven name like ADRX, they help flag potential changes between clinical milestones without constant manual review. This approach has become a regular part of how I track volatile biotech positions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ADRX

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5871 Oberlin Drive
Phone
+1 858 283-9472
Employees
100
Web
https://www.adarx.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.